Merck: This Cancer-Drug Powerhouse Could Be a Core Dividend
A dividend-focused investor might overlook Merck at first glance. Yet this cancer‑drug powerhouse blends steady cash ...
Retirement planning is essential for achieving financial stability in your later years. Learn why it's never too early to start planning.
21,478 articlesA dividend-focused investor might overlook Merck at first glance. Yet this cancer‑drug powerhouse blends steady cash ...
A major investment advisor just boosted its stake in the Invesco BulletShares 2027 Corporate Bond ETF by about $76 mi...
Income-focused investors are tuning in to Energy Transfer for a high-yield dividend and steady growth. This guide exp...
A private Philadelphia moment between Beyoncé and Jay-Z offers more than star power. This piece breaks down the finan...
Looking at Royal Caribbean in 2026, investors want clarity: is it a buy, hold, or sell? This guide breaks down the ca...
A Brookings study released this spring estimates ICE enforcement costs the economy about 668,000 jobs, unraveling the...
In close CEO searches, the runner-up often lands a multi-million retention package. This trend shows up in Disney, Mo...
A cheaper Nasdaq-100 wrapper from Invesco is drawing attention as QQQM tracks the same index with lower fees. The mov...
The cyber threat landscape is expanding, and AI is changing the game. This article explains why the cybersecurity mar...
Tech giants are investing heavily in AI, yet leaders warn that compute costs may outstrip wages. New MIT findings and...
Geopolitical shocks have a long echo in the markets. This piece uses 86 years of history to explain how Iran tensions...
High-profile legal headlines can ripple into everyday money matters. This article uses the James Harden case to illus...